Latest News and Press Releases

MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment

韓国とオーストラリアの保健当局からも承認取得、台湾は2024年第4四半期に承認取得予定米国で初の患者無作為化 コネチカット州ダンバリ, Sept. 18, 2024 (GLOBE NEWSWIRE) -- 内分泌疾患および希少肺疾患患者を対象とした革新的な吸入治療薬および機器の開発・商業化に取り組んでいる マンカインド・コーポレーション (MannKind Corporation)...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled...

KENT KRESA TO RETIRE FROM MANNKIND’S BOARD OF DIRECTORS; STEVEN B. BINDER TO BE APPOINTED TO THE BOARD

2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung...

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

MANNKIND CORPORATION TO HOLD 2024 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 7, 2024

INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED